Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients
Frederik Nevens, Jane N. Zuckerman, Andrew K. Burroughs, Maria‐Christina Jung, José M. Bayas, Birgit Kallinowski, Enrique Fraga Rivas, Christophe Duvoux, Peter Neuhaus, Faouzi Saliba, Maria Buti, Jean‐Pierre Zarski, Fernando Pons, Claire Vanlemmens, Virginie Hamtiaux, Michel Stoffel – 26 September 2006 – Patients with chronic liver disease are at higher risk of hepatitis B (HB) virus infection before and after liver transplantation, and they commonly have a suboptimal immune response to HB vaccines.